<DOC>
	<DOC>NCT00929162</DOC>
	<brief_summary>The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.</brief_summary>
	<brief_title>ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven diagnosis of: Epithelial ovarian carcinoma Fallopian tube carcinoma Primary serous peritoneal carcinoma Radiologically documented measurable disease according to RECIST criteria assessed by Computerised Tomography (CT) or Magnetic Resonance Imaging MRI) or radiologically documented nonmeasurable (but evaluable) disease. Advanced disease not amenable to curative surgery or radiotherapy at the time of study entry with evidence of disease recurrence or progression at least 6 months following treatment cessation of firstline platinum containing therapy Clinical evidence of central nervous system (CNS) metastases Nonepithelial ovarian cancer, including malignant mixed Mullerian tumours and mucinous carcinoma of the peritoneum Tumour of borderline malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ovarian</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>sensitive</keyword>
	<keyword>ZD4054</keyword>
</DOC>